INDIANAPOLIS (dpa-AFX) - The U.S. Food and Drug Administration has given the green light to Foundayo, a new daily weight-loss pill from Eli Lilly and Company, which shakes things up in the obesity treatment market.
This pill contains orforglipron, and in clinical trials, patients dealing with obesity managed to lose around 12 percent of their body weight on average after 72 weeks when taking the highest dosage. Foundayo will be available in six different dose levels, priced between $149 and $349 monthly for those without insurance.
What's great about Foundayo is that, unlike injectable obesity medications, it can be taken any time of day and doesn't have to be with food, making it more convenient for users. Eli Lilly plans to start shipments on Monday.
This approval ramps up competition with Novo Nordisk, which had their Wegovy pill approved in late 2025. Both medications yield similar weight-loss results, yet they use different active ingredients.
Additionally, Eli Lilly is looking to get orforglipron approved for treating Type 2 diabetes later this year, as studies have shown it helps improve blood sugar control in diabetic patients.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
